The majority of breast cancers express the estrogen receptor (ERα) and agents targeting this
pathway represent the main treatment modality. Endocrine therapy has proven successful in …

In metastatic hormone receptor-positive breast cancer, ESR1 mutations are a common
cause of acquired resistance to the backbone of therapy, estrogen deprivation by aromatase …

The hormone receptor oestrogen receptor-α (ER) orchestrates physiological mammary
gland development, breast carcinogenesis and the progression of breast tumours into lethal …

The acquisition of ligand‐independent ESR1 mutations during aromatase inhibitor therapy
in metastatic estrogen receptor (ER)‐positive breast cancer is a common mechanism of …

The estrogen receptor (ER) is a validated target for the treatment of estrogen receptor-
positive (ER+) breast cancer. Here, we describe the design, synthesis, and extensive …

Invasive lobular carcinoma (ILC) is the most common of the breast cancer special types,
accounting for up to 15% of all breast cancer cases. ILCs are noted for their lack of E …

Breast cancer accounts for 25% of the cancers in women worldwide. The most common
subtype of breast cancer diagnosed is hormone receptor positive, which expresses the …

Protein phosphorylation, catalyzed by protein kinases (PKs), is one of the most important
post-translational modifications (PTMs), and involved in regulating almost all of biological …

A significant proportion of patients with oestrogen receptor (ER) positive breast cancers (BC)
develop resistance to endocrine treatments (ET) and relapse with metastatic disease. Here …

The estrogen receptor is a vital receptor for therapeutic targets in estrogen receptor-positive
breast cancer. The main strategy for the treatment of estrogen receptor-positive breast …